Oct 20, 2025 | Legal Compliance
The FDA recently issued warning letters to six companies, five in the U.S. and one in Germany, for selling compounded versions of retatrutide, an experimental weight-loss drug that is not yet approved for public use. The agency’s message is straightforward:...
Oct 20, 2025 | Legal Compliance
As the medical aesthetics and wellness industry continues to expand, compounded products, from peptides and hormones to injectables, have become commonplace in medspas and functional medicine practices. However, the FDA has issued a strong warning: certain bulk drug...
Oct 20, 2025 | Legal Compliance
In a closely watched case involving compounded GLP-1 drugs, a federal judge in Delaware has dismissed Eli Lilly’s lawsuit against Strive Pharmacy, sending a clear message: national pharma litigation doesn’t override basic jurisdictional rules. Lilly alleged Strive...
Sep 13, 2025 | Legal Compliance, Risk Management, State-Specific Regulations
Cal/OSHA has released its revised Safety and Health Protection on the Job poster, effective July 2025. California employers must display the updated notice in a clearly visible location. Failure to post it, or to comply with the rules it summarizes, can lead to...
Sep 8, 2025 | Legal Compliance, News
September 8, 2025 – A significant legal development unfolded last week when U.S. District Judge Andre Birotte Jr. dismissed Eli Lilly’s lawsuit against Willow Health, a telehealth company compounding tirzepatide. The ruling is the latest in a series of high-profile...
Aug 13, 2025 | Legal Compliance, Marketing & Advertising Law, News
If you’ve been keeping an eye on the wellness world lately, you’ve probably noticed a new buzzword popping up everywhere: NAD+. From IV drips at high-end med spas to celebrity biohacking routines, it’s quickly become one of the most talked-about treatments for...
